Phase 2 clinical study of evaluation of efficacy of switch to eribulin chemotherapy in patients with locally advanced breast cancer or metastatic breast cancer who are not responsive to combination regimen of Docetaxel, Doxorubicin and Cyclophosphamide (TAC) and continuation of TAC chemotherapy in responding patients to TAC
Not Applicable
Recruiting
- Conditions
- ocally advanced and/or metastatic breast cancer patients
- Registration Number
- JPRN-UMIN000015838
- Lead Sponsor
- Saitama Medical Univeristy International Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
Patients who do not have informed consent on paper Patients who have uncontroled severe diabetes, infection , or other malignancy Patients whom doctor consider this treatment are suitable for.
Study & Design
- Study Type
- Interventional,observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To evaluate radiological response to eribulin in TAC non-responding patients
- Secondary Outcome Measures
Name Time Method